MX377653B - Producto y uso para normalización de la viscoelasticidad del moco. - Google Patents

Producto y uso para normalización de la viscoelasticidad del moco.

Info

Publication number
MX377653B
MX377653B MX2015013040A MX2015013040A MX377653B MX 377653 B MX377653 B MX 377653B MX 2015013040 A MX2015013040 A MX 2015013040A MX 2015013040 A MX2015013040 A MX 2015013040A MX 377653 B MX377653 B MX 377653B
Authority
MX
Mexico
Prior art keywords
normalization
product
mucus viscoelasticity
mucus
viscoelasticity
Prior art date
Application number
MX2015013040A
Other languages
English (en)
Spanish (es)
Other versions
MX2015013040A (es
Inventor
Peter B Heifetz
Original Assignee
Orpro Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orpro Therapeutics Inc filed Critical Orpro Therapeutics Inc
Publication of MX2015013040A publication Critical patent/MX2015013040A/es
Publication of MX377653B publication Critical patent/MX377653B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/005—Sprayers or atomisers specially adapted for therapeutic purposes using ultrasonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0051—Oxidoreductases (1.) acting on a sulfur group of donors (1.8)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y108/00—Oxidoreductases acting on sulfur groups as donors (1.8)
    • C12Y108/04—Oxidoreductases acting on sulfur groups as donors (1.8) with a disulfide as acceptor (1.8.4)
    • C12Y108/0401—Adenylyl-sulfate reductase (thioredoxin) (1.8.4.10)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y108/00—Oxidoreductases acting on sulfur groups as donors (1.8)
    • C12Y108/01—Oxidoreductases acting on sulfur groups as donors (1.8) with NAD+ or NADP+ as acceptor (1.8.1)
    • C12Y108/01009—Thioredoxin-disulfide reductase (1.8.1.9), i.e. thioredoxin-reductase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Physiology (AREA)
  • Analytical Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
MX2015013040A 2013-03-15 2014-03-17 Producto y uso para normalización de la viscoelasticidad del moco. MX377653B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361792198P 2013-03-15 2013-03-15
PCT/US2014/030545 WO2014145735A2 (en) 2013-03-15 2014-03-17 Product and process for mucus viscosity normalization

Publications (2)

Publication Number Publication Date
MX2015013040A MX2015013040A (es) 2016-05-24
MX377653B true MX377653B (es) 2025-03-11

Family

ID=51527945

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015013040A MX377653B (es) 2013-03-15 2014-03-17 Producto y uso para normalización de la viscoelasticidad del moco.

Country Status (11)

Country Link
US (3) US9168290B2 (enExample)
EP (1) EP2968481B1 (enExample)
JP (1) JP6672139B2 (enExample)
KR (2) KR20210068606A (enExample)
CN (1) CN105188738B (enExample)
AU (1) AU2014232520B2 (enExample)
CA (1) CA2906868A1 (enExample)
IL (1) IL241320B (enExample)
MX (1) MX377653B (enExample)
RU (1) RU2750211C2 (enExample)
WO (1) WO2014145735A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2635581C (en) 2005-12-28 2017-02-28 Vertex Pharmaceuticals Incorporated Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
AU2014232520B2 (en) 2013-03-15 2019-04-04 Orpro Therapeutics, Inc. Product and process for mucus viscosity normalization
RU2749213C2 (ru) 2014-10-07 2021-06-07 Вертекс Фармасьютикалз Инкорпорейтед Сокристаллы модуляторов регулятора трансмембранной проводимости при кистозном фиброзе
US10542961B2 (en) 2015-06-15 2020-01-28 The Research Foundation For The State University Of New York System and method for infrasonic cardiac monitoring
CN106868090B (zh) * 2017-03-28 2020-09-29 王绪友 一种医学检验用痰液处理方法
CN107630065A (zh) * 2017-11-02 2018-01-26 蔡慧娜 一种在支原体液体培养时使标本均匀分散的方法
US20210213134A1 (en) * 2018-05-17 2021-07-15 Orpro Therapeutics, Inc. Thiol-based multivalent drug delivery compositions
JP2023509462A (ja) * 2020-01-03 2023-03-08 オアプロ セラピューティクス インコーポレイテッド チオレドキシン活性を有する組成物および関連方法
CN115200954B (zh) * 2022-06-28 2025-05-06 珠海大略科技有限公司 一种降低唾液粘度的方法及其应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3091569A (en) 1960-08-26 1963-05-28 Mead Johnson & Co Mucolytic-nu-acylated sulfhydryl compositions and process for treating animal mucus
US3502779A (en) 1966-08-18 1970-03-24 Calbiochem Process of mucolysis
US3683069A (en) * 1970-02-19 1972-08-08 Michel Hooreman Enzymatic products which optimize the viscosity of mucuses and their applications
US4738841A (en) * 1985-08-28 1988-04-19 Repligen Corporation Use of thioredoxin, thioredoxin-derived, or thioredoxin-like dithiol peptides in hair care preparations
US4771036A (en) 1986-02-10 1988-09-13 Trustees Of Columbia University In The City Of New York Method and ophthalmic composition for the prevention and reversal of cataracts
SE8903003D0 (sv) 1989-09-12 1989-09-12 Astra Ab Novel medical use
US5380758A (en) 1991-03-29 1995-01-10 Brigham And Women's Hospital S-nitrosothiols as smooth muscle relaxants and therapeutic uses thereof
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5908611A (en) 1995-05-05 1999-06-01 The Scripps Research Institute Treatment of viscous mucous-associated diseases
US5985261A (en) 1996-06-28 1999-11-16 National Jewish Medical And Research Center Use of thioredoxin-like molecules for induction of MnSOD to treat oxidative damage
JPH10191977A (ja) 1997-01-14 1998-07-28 Oriental Yeast Co Ltd チオレドキシン改変体及び該改変体を含むａｐ−１の転写活性能を増強する因子
DE19711052C2 (de) 1997-03-03 1999-09-23 Hans Rommelspacher Verwendung von 2-Methyl-thiazolidin-2,4-dicarbonsäure als Mukolytikum
US7585645B2 (en) 1997-05-27 2009-09-08 Sembiosys Genetics Inc. Thioredoxin and thioredoxin reductase containing oil body based products
US5925334A (en) 1997-08-27 1999-07-20 Rubin; Bruce K. Use of surface active agents to promote mucus clearance
JP4206272B2 (ja) 2001-03-29 2009-01-07 サイナージィ ファーマスーティカルズ、インコーポレイテッド 組織炎症及び発癌を治療するためのグアニル酸シクラーゼ受容体アゴニスト
EP1507852A4 (en) 2001-05-04 2005-12-28 Xencor Inc NUCLEIC ACIDS AND PROTEINS WITH THIORODOXIN REDUCED EFFECT
US20030194798A1 (en) 2001-05-24 2003-10-16 Surber Mark W. Minicell compositions and methods
US20060148057A1 (en) * 2002-08-02 2006-07-06 Wang Min Thioredoxin mutants and uses thereof
CN1694726A (zh) * 2002-09-10 2005-11-09 国家杰威什医疗及研究中心 用于液化粘液或痰液的产品和方法
AU2003270561B2 (en) * 2002-09-10 2009-04-09 National Jewish Health Product and process for liquefaction of mucus or sputum
WO2004087917A1 (ja) 2003-03-31 2004-10-14 National Institute Of Advanced Industrial Science And Technology チオレドキシン改変体
RU2253484C1 (ru) * 2003-09-30 2005-06-10 Российский научный центр восстановительной медицины и курортологии Министерства здравоохранения Российской Федерации Способ лечения хронического бронхолегочного процесса при врожденных пороках развития легких у детей
WO2005094269A2 (en) 2004-03-24 2005-10-13 National Jewish Medical And Research Center Mucolytic and anti-elastase compounds and methods of use thereof
EP1758990A2 (en) 2004-06-11 2007-03-07 Syngenta Limited Method for ameliorating an inflammatory skin condition
GB2416122A (en) 2004-07-12 2006-01-18 Ipsen Ltd Botulinum neurotoxin composition
GB0503640D0 (en) 2005-02-22 2005-03-30 Syngenta Ltd Improvements in or relating to organic compounds
AU2014232520B2 (en) * 2013-03-15 2019-04-04 Orpro Therapeutics, Inc. Product and process for mucus viscosity normalization
US20210213134A1 (en) 2018-05-17 2021-07-15 Orpro Therapeutics, Inc. Thiol-based multivalent drug delivery compositions
JP2023509462A (ja) 2020-01-03 2023-03-08 オアプロ セラピューティクス インコーポレイテッド チオレドキシン活性を有する組成物および関連方法

Also Published As

Publication number Publication date
EP2968481A2 (en) 2016-01-20
US9168290B2 (en) 2015-10-27
EP2968481A4 (en) 2016-07-13
WO2014145735A2 (en) 2014-09-18
US20210254025A1 (en) 2021-08-19
CA2906868A1 (en) 2014-09-18
RU2750211C2 (ru) 2021-06-24
JP6672139B2 (ja) 2020-03-25
US20160230149A1 (en) 2016-08-11
WO2014145735A9 (en) 2015-05-07
KR20210068606A (ko) 2021-06-09
WO2014145735A3 (en) 2014-12-31
IL241320B (en) 2022-02-01
CN105188738B (zh) 2025-11-07
IL241320A0 (en) 2015-11-30
JP2016517446A (ja) 2016-06-16
US12390511B2 (en) 2025-08-19
HK1220354A1 (zh) 2017-05-05
AU2014232520B2 (en) 2019-04-04
MX2015013040A (es) 2016-05-24
AU2014232520A1 (en) 2015-09-24
EP2968481B1 (en) 2020-11-04
RU2015143953A (ru) 2017-04-21
KR20160007496A (ko) 2016-01-20
US20140271599A1 (en) 2014-09-18
NZ711983A (en) 2021-09-24
RU2015143953A3 (enExample) 2018-04-02
CN105188738A (zh) 2015-12-23

Similar Documents

Publication Publication Date Title
MX377653B (es) Producto y uso para normalización de la viscoelasticidad del moco.
MX2017012206A (es) Proliferacion ex vivo de celulas epiteliales.
CL2012003075A1 (es) Composicion farmaceutica en solucion de pazopanib, estable y para uso oftalmico; metodo para la preparacion de dicha solucion.
DOP2015000304A (es) Inhibidores cristalinos de bromodominios
UA114901C2 (uk) Інгібітори асс та їх застосування
HUE072090T2 (hu) Magas viszkoelaszticitású és magas kohézióképességû hialuronsav töltõanyag
WO2015002724A3 (en) SC-β CELLS AND COMPOSITIONS AND METHODS FOR GENERATING THE SAME
BR112014021325A2 (pt) Formulação farmacêutica líquida e formulação liofilizada
MX2021015789A (es) Reduccion de la viscosidad de formulaciones farmaceuticas.
EP3129465A4 (en) Hydrogel compositions for use in cell expansion and differentiation
CO2019008103A2 (es) Composiciones farmacéuticas para terapia de combinación
BRPI0511396A (pt) derivados de retinal e métodos para uso no tratamento de enfermidades visuais
BR112017005660A2 (pt) novos ativadores de guanilato ciclase solúvel e sua utilização
UY34008A (es) ?formas en estado sólido de inhibidor de hiv, composición farmacéutica, uso de la misma, y procesos para preparar dichas formas?.
BR112016029013A2 (pt) aperfeiçoamento em composição nasal e método de utilização do mesmo
MX386055B (es) Uso de medicamentos para disminuir la evolución de la enfermedad de parkinson.
BR112014003139A2 (pt) musgo de turfa umectável resistente à lixiviação, método de preparação, e método de uso
WO2014153009A3 (en) Thiosaccharide mucolytic agents
BR112015032526A2 (pt) composições anticaspa e métodos de uso das mesmas
BR112015028703A2 (pt) curativo de ferimentos compreendendo uma composição antimicrobiana
WO2014153495A3 (en) Novel stat3 inhibitors
MX2019011196A (es) Neurotoxinas botulinas para uso en terapia.
WO2014146111A3 (en) Analgesic compounds and methods of use
EP4226937A3 (en) Non-neuroinvasive viruses and uses thereof
PH12018502139A1 (en) Phosphaplatin liquid formulations

Legal Events

Date Code Title Description
FG Grant or registration